Skip to content

Clinical validation of weak acid buffered physiological seawater nasal cavity nursing sprayer

Clinical validation of weak acid buffered physiological seawater nasal cavity nursing sprayer

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17013831
Enrollment
Unknown
Registered
2017-12-12
Start date
2014-06-30
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis

Interventions

experiment group:Weak acid buffered physiological seawater nasal cavity nursing sprayer
control group:Physiological seawater nasal spray

Sponsors

Eye and ENT Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) the standard of diagnosis of chronic rhinosinusitis (cpos2012 Kunming standard); (2) aged between 18-65 years; (3) informed consent, voluntary subjects, and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) cold and fever, or for patients with acute rhinitis, acute sinusitis, allergic rhinitis, and severe nasal polyps; (2) the episodes of asthma have been merged and the symptoms are more serious; (3) severe nasal trauma, severe metabolic disorder of sodium chloride and allergies; (4) people under the age of 18 or over 65 years of age, or for women in pregnancy and lactation; (5) there are serious primary cardiovascular diseases, liver diseases, kidney diseases, hematological diseases, lung diseases, or severe diseases that affect their survival, such as cancer or AIDS, and severe hypertension; (6) mentally or legally disabled patients; (7) suspect or indeed have a history of alcohol abuse or drug abuse. Or according to the researchers' judgement, other diseases such as decreasing the possibility of entry or complicating the entry group, such as frequent changes in working environment, are likely to cause loss of visit; (8) a person who is known to be allergic to the composition of the drug in clinical trials; (9) patients who are participating in other clinical trials of drugs; (10) patients with the following combination drugs: glucocorticoids, macrolides, antibacterial agents, mucus dissolving and promoting drainage agents, anti allergic drugs, traditional Chinese medicine and blood reducing agents.

Design outcomes

Primary

MeasureTime frame
Safety and effecacy;

Countries

China

Contacts

Public ContactDehui Wang

83 Fenyang Road, Shanghai, China

wangdehuient@sina.com+86 021-64377134-2202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026